转录因子EB相关自噬在多发性骨髓瘤治疗中的作用及机制
该研究体外培养多发性骨髓瘤细胞株RPMI8226和U266,用硼替佐米和(或)西拉美新处理,检测细胞增殖及TFEB、自噬相关因子的mRNA和蛋白表达。结果显示两药联用对MM细胞增殖有协同抑制作用,与自噬表达增强及TFEB核转位增加相关。
要点
- 硼替佐米和西拉美新联用对MM细胞株增殖有协同抑制作用。
- 两药处理后细胞质TFEB表达下降、细胞核TFEB表达上升,提示TFEB核转位增强。
- 自噬相关因子LC3B、Beclin1、LAMP1表达上升,p62表达下降。
核心结论
- 硼替佐米和西拉美新具有协同抑制MM细胞增殖的作用,与其诱导MM细胞株自噬表达增强相关,发生核转位的TFEB表达亦增强。
研究设计与样本
- 体外培养多发性骨髓瘤细胞株RPMI8226及U266,以一定浓度的硼替佐米和西拉美新处理。
- 采用CCK-8法检测细胞增殖,实时定量PCR和Western blot法检测TFEB、LC3B、Beclin1、p62、LAMP1的mRNA和蛋白相对表达量。
主要发现
- 随着硼替佐米浓度增加及作用时间延长,两个细胞系的增殖抑制率增高(P<0.05)。
- 硼替佐米和西拉美新联用对上述MM细胞株的增殖有协同抑制作用(P<0.05)。
- 空白对照组、单药组、联合用药组处理后,细胞质中TFEB的mRNA和蛋白相对表达量依次下降(P<0.05),细胞核中TFEB的mRNA和蛋白相对表达量依次上升(P<0.05)。
- 自噬相关因子LC3B、Beclin1、LAMP1的mRNA和蛋白相对表达量依次上升,p62的mRNA和蛋白相对表达量依次下降(P<0.05)。
临床怎么用
- 提示硼替佐米联合西拉美新可能通过增强TFEB核转位及自噬水平协同抑制MM细胞增殖,为后续调控机制研究提供体外依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To clarify the effects of bortezomib combined with or without siramesine on the proliferation of multiple myeloma cell lines, the expression changes of transcription factor EBC (TFEB) nuclear translocation and the level of autophagy, and to provide basis for further exploring the regulation mechanism of transcription factor TFEB on autophagy. Methods: The multiple myeloma cell lines RPMI8226 and U266 were cultured in vitro, and the multiple myeloma cells were treated with a certain concentration of bortezomib and siramesine. The changes of cell proliferation inhibition were detected by CCK-8 method. Real time PCR and Western blot were used to detect the relative expression of TFEB, autophagy-related factor LC3B, Beclin1, p62, LAMP1 mRNA and protein. Results: As the concentration of bortezomib increased and the duration of action increased, the proliferation inhibition rates of the two cell lines gradually increased (P<0.05) . The combination of the two drugs has a synergistic inhibitory effect on the proliferation of the above-mentioned multiple myeloma cell lines (P<0.05) . In the blank control group, single drug group, and combination drug group, the relative expression of TFEB mRNA and protein in the cytoplasm decreased sequentially (P<0.05) , and the relative expression of TFEB mRNA and protein in the nucleus increased sequentially (P<0.05) . The relative expression of autophagy-related factors LC3B, Beclin1, LAMP1 mRNA and protein increased sequentially, and the relative expression of p62 mRNA and protein decreased sequentially (P<0.05) . Conclusion: Bortezomib and siramesine can synergistically inhibit the growth of multiple myeloma cells, which is related to the increased autophagy expression in multiple myeloma cell lines and the expression of TFEB with nuclear translocation is also enhanced. 目的: 明确硼替佐米和(或)西拉美新作用于多发性骨髓瘤(MM)细胞株后细胞增殖、转录因子EB(TFEB)核转位表达变化及自噬水平,为进一步探讨TFEB对自噬的调控机制提供依据。 方法: 体外培养MM细胞株RPMI8226及U266,并以一定浓度的硼替佐米和西拉美新处理MM细胞,CCK-8法检测细胞增殖,实时定量PCR和Western blot法检测TFEB、自噬相关因子LC3B、Beclin1、p62、LAMP1的mRNA和蛋白相对表达量。 结果: 随着硼替佐米浓度增加及作用时间延长,两个细胞系的增殖抑制率增高(P<0.05)。硼替佐米和西拉美新联用对上述MM细胞株的增殖有协同抑制作用(P<0.05)。空白对照组、单药组、联合用药组处理MM细胞株后,细胞质中TFEB的mRNA和蛋白相对表达量依次下降(P<0.05),细胞核中TFEB的mRNA和蛋白相对表达量依次上升(P<0.05),自噬相关因子LC3B、Beclin1、LAMP1的mRNA和蛋白相对表达量依次上升,p62的mRNA和蛋白相对表达量依次下降(P<0.05)。 结论: 硼替佐米和西拉美新具有协同抑制MM细胞增殖作用,与其诱导MM细胞株自噬表达增强相关,发生核转位的TFEB表达亦增强。.
引用
- Zhang ZH, Zhang RJ, Han N, et al. [Transcription factor EB related autophagy in the treatment of multiple myeloma and its mechanism]. Zhonghua Xue Ye Xue Za Zhi. 2021. PMID: 34218584. doi:10.3760/cma.j.issn.0253-2727.2021.05.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。